BIOMAT Database Logo BIOMAT Database Logo

Potentially serious interaction of warfarin with sulphinpyrazone. 1981

P L Thompson, and C Serjeant

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011517 Prothrombin Time Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. Factors measured are FIBRINOGEN; PROTHROMBIN; FACTOR V; FACTOR VII; and FACTOR X. It is used for monitoring anticoagulant therapy with COUMARINS. Quick Test,Russell's Viper Venom Time,Thrombotest,Russell Viper Venom Time,Russells Viper Venom Time,Prothrombin Times,Test, Quick,Time, Prothrombin,Times, Prothrombin
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013442 Sulfinpyrazone A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. Sulfoxyphenylpyrazolidin,Anturan,Anturane,Apo-Sulfinpyrazone,Nu-Sulfinpyrazone,Sulphinpyrazone,Apo Sulfinpyrazone,Nu Sulfinpyrazone
D014859 Warfarin An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide. 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one,Aldocumar,Apo-Warfarin,Coumadin,Coumadine,Gen-Warfarin,Marevan,Tedicumar,Warfant,Warfarin Potassium,Warfarin Sodium,Potassium, Warfarin,Sodium, Warfarin

Related Publications

P L Thompson, and C Serjeant
Interaction of sulphinpyrazone with warfarin.
January 1982, European journal of clinical pharmacology,
P L Thompson, and C Serjeant
Biphasic sulphinpyrazone-warfarin interaction.
April 1981, British medical journal (Clinical research ed.),
P L Thompson, and C Serjeant
Sulphinpyrazone and warfarin: a probable drug interaction.
March 1980, Lancet (London, England),
P L Thompson, and C Serjeant
Potentiation of warfarin action by sulphinpyrazone.
February 1980, Lancet (London, England),
P L Thompson, and C Serjeant
Sulphinpyrazone and warfarin after myocardial infarction.
August 1979, British medical journal,
P L Thompson, and C Serjeant
Sulphinpyrazone and warfarin after myocardial infarction.
July 1979, British medical journal,
P L Thompson, and C Serjeant
Serious interaction between warfarin and oral terbinafine.
February 1998, BMJ (Clinical research ed.),
P L Thompson, and C Serjeant
[Noscapine and warfarin--a potentially dangerous interaction].
March 2009, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
P L Thompson, and C Serjeant
Ciprofloxacin interaction with sodium warfarin: a potentially dangerous side effect.
November 1991, The American journal of emergency medicine,
P L Thompson, and C Serjeant
Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone.
January 1982, Clinical pharmacokinetics,
Copied contents to your clipboard!